On Sept. 17, following nearly three years of litigation and a six-week trial, California’s Department of Justice delivered its closing arguments in a landmark case against RealOptions Obria and Heartbeat International, seeking to stop their use of “false and misleading claims to advertise abortion pill reversal” (APR), as Attorney General Rob Bonta described it in a press release.
APR is the unproven and potentially dangerous flooding of the body with a high dosage of progesterone after taking mifepristone, the first pill in the FDA-approved medication abortion protocol, but before taking misoprostol, the second approved pill in the sequence.
APR has become an increasingly central tactic in CPCs’ relentless post-Dobbs efforts to persuade what they call “abortion-vulnerable” pregnant women to carry their pregnancies to term.
The trial court is expected to issue its ruling by Dec. 16, within the 90-day period allotted under California law. Given the evidence presented at trial, a ruling in California’s favor could mark a significant victory in efforts to hold CPCs accountable for promoting false and misleading claims about a procedure that the American College of Obstetricians and Gynecologists has denounced as “unproven and unethical.” Such a decision would also send a powerful message: The First Amendment does not give organizations a free pass to mislead pregnant women about their medical care.











